The biotech will stop developing two drugs and lay off nearly three-quarters of its staff after its lead therapy wasn’t as potent in early testing as the company expected.

CES is in full swing, and we're seeing all of the most interesting tech that our favorite companies have to offer. Among the ...

Residents impacted by the California wildfires may get inundated with calls from people offering to handle their claims for ...

IGM Biosciences is again cutting staff as it scraps an autoimmune-drug trial after failing to achieve the desired results.

ASX sectors including telcos and energy are strong, but some are overpriced, while retail and healthcare show promise, says ...

Illumina has begun rolling out a series of updates to its top-of-the-line DNA sequencer models, with the goal of making the ...

The first technology lab to bring together automakers, cellular network operators, traffic technology companies, semiconductor manufacturers and Departments of Transportation to develop connected ...

A clinical-stage biotechnology company will advance a novel autologous chimeric antigen receptor T-cell therapy that targets ...

Big microLED displays are very expensive, but one company is making the technology cheaper to create a rollable, transparent, ...

By mid-2025, the biotech will split into two entities: a new, as-yet-unnamed innovative medicines specialist and a cell ...

Roche's strategic acquisition of Poseida Pharmaceuticals positions them as a leader in the allogeneic cell therapy market.

Multiple wildfires, including the Palisades Fire and Eaton Fire, are raging across southern California early Thursday, ...